Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydromyricetin vs Metformin in Type 2 Diabetes Mellitus
NCT03606694Phase 2Unknown
- Sponsor
- Universidad de Guadalajara
- Start
- Oct 2019
- Primary completion
- Dec 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dihydromyricetin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Universidad de Guadalajara. Primary endpoints: Fasting Glucose at 12 weeks, Postprandial Glucose at 12 weeks and 4 more. Status: unknown.
02
Drugs
dihydromyricetin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03606694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606694.